BR0208275A - Composições farmacêuticas para tratamento de arteriosclerose - Google Patents
Composições farmacêuticas para tratamento de arterioscleroseInfo
- Publication number
- BR0208275A BR0208275A BR0208275-6A BR0208275A BR0208275A BR 0208275 A BR0208275 A BR 0208275A BR 0208275 A BR0208275 A BR 0208275A BR 0208275 A BR0208275 A BR 0208275A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- treating atherosclerosis
- treating
- group
- arteriosclerosis
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 2
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Indole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001078569 | 2001-03-19 | ||
| JP2001401289 | 2001-12-28 | ||
| PCT/JP2002/002585 WO2002074342A1 (en) | 2001-03-19 | 2002-03-19 | Remedies for arteriosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0208275A true BR0208275A (pt) | 2004-04-13 |
Family
ID=26611547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0208275-6A BR0208275A (pt) | 2001-03-19 | 2002-03-19 | Composições farmacêuticas para tratamento de arteriosclerose |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040248898A1 (enExample) |
| EP (2) | EP1378246B1 (enExample) |
| JP (1) | JP4499361B2 (enExample) |
| KR (1) | KR100908968B1 (enExample) |
| CN (1) | CN1553814B (enExample) |
| AT (1) | ATE428425T1 (enExample) |
| BR (1) | BR0208275A (enExample) |
| CA (1) | CA2441110C (enExample) |
| DE (1) | DE60231969D1 (enExample) |
| ES (1) | ES2324766T3 (enExample) |
| MX (1) | MXPA03008440A (enExample) |
| PT (1) | PT1378246E (enExample) |
| TW (1) | TWI314457B (enExample) |
| WO (1) | WO2002074342A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2002000621A1 (ja) * | 2000-06-29 | 2004-04-22 | 塩野義製薬株式会社 | Ｘ型ｓＰＬＡ２阻害作用を有する化合物 |
| US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| NZ554491A (en) | 2004-10-12 | 2009-07-31 | Decode Genetics Ehf | Sulfonamide peri-substituted bicyclics for occlusive artery disease |
| PT1852433E (pt) | 2004-10-29 | 2012-02-08 | Zeria Pharm Co Ltd | Derivados de carbazole, seus solvatos ou seus sais farmaceuticamente aceitáveis |
| MX2008005666A (es) | 2005-11-03 | 2009-03-02 | Ilypsa Inc | Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2. |
| WO2007056275A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors |
| WO2007137042A2 (en) | 2006-05-16 | 2007-11-29 | Decode Genetics, Ehf. | Process for preparing 7- (acryl0yl) -ind0les |
| US8048880B2 (en) * | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
| CN101742907A (zh) * | 2007-05-03 | 2010-06-16 | 安塞拉制药有限公司 | 采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常 |
| US20090062369A1 (en) * | 2007-08-31 | 2009-03-05 | Joaquim Trias | Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels |
| WO2010038104A1 (en) * | 2008-10-03 | 2010-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event. |
| KR101357438B1 (ko) | 2009-04-29 | 2014-02-06 | 아마린 코포레이션 피엘씨 | Ｅｐａ 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법 |
| KR101037404B1 (ko) * | 2010-12-07 | 2011-05-30 | 박철형 | 가변설치가 가능한 압출본체에 의한 천장용 엘이디 조명등 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| EP0658205B1 (en) * | 1993-06-25 | 2000-03-15 | Smithkline Beecham Plc | Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy |
| US5498608A (en) * | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
| JP3109974B2 (ja) | 1994-04-01 | 2000-11-20 | イーライ・リリー・アンド・カンパニー | １Ｈ−インドール−３−グリオキシルアミドｓＰＬＡ２阻害剤 |
| MX9700511A (es) | 1994-07-21 | 1997-04-30 | Lilly Co Eli | Inhibidores de spla2 de indolizina. |
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| US6214876B1 (en) * | 1994-07-21 | 2001-04-10 | Eli Lilly And Company | Indene-1-acetamide sPLA2 inhibitors |
| US6160175A (en) | 1995-12-13 | 2000-12-12 | Eli Lilly And Company | Naphthyl acetamides as sPLA2 inhibitors |
| EP0779273B1 (en) | 1995-12-13 | 2002-03-20 | Eli Lilly And Company | Naphthyl glyoxamides as sPLA2 inhibitors |
| TR199900956T2 (xx) * | 1996-10-30 | 1999-07-21 | Eli Lilly And Company | S�bstit�e edilmi� trisiklik bile�imler. |
| US6353128B1 (en) | 1996-12-03 | 2002-03-05 | Eli Lilly And Company | Phenyl acetamides as sPLA2 inhibitors |
| US5916922A (en) | 1996-12-03 | 1999-06-29 | Eli Lilly And Company | Phenyl glyoxamides as SPLA2 inhibitors |
| ID18983A (id) | 1996-12-04 | 1998-05-28 | Lilly Co Eli | Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia |
| US5919774A (en) | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
| WO1999051605A1 (en) | 1998-03-31 | 1999-10-14 | Shionogi & Co., Ltd. | PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR |
| BR9911048A (pt) * | 1998-05-21 | 2001-02-06 | Shionogi & Co | Inibidor de spla2 de pirrolo[1,2-b]piridazina |
| CA2346334A1 (en) * | 1998-10-14 | 2000-04-20 | Shionogi & Co., Ltd. | Composition for treating or preventing ischemia reperfusion injury |
| US6756376B1 (en) * | 1999-11-15 | 2004-06-29 | Shionogi & Co., Ltd. | Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities |
| JPWO2002000621A1 (ja) * | 2000-06-29 | 2004-04-22 | 塩野義製薬株式会社 | Ｘ型ｓＰＬＡ２阻害作用を有する化合物 |
-
2002
- 2002-03-18 TW TW091105096A patent/TWI314457B/zh not_active IP Right Cessation
- 2002-03-19 MX MXPA03008440A patent/MXPA03008440A/es active IP Right Grant
- 2002-03-19 AT AT02705327T patent/ATE428425T1/de not_active IP Right Cessation
- 2002-03-19 EP EP02705327A patent/EP1378246B1/en not_active Expired - Lifetime
- 2002-03-19 CA CA2441110A patent/CA2441110C/en not_active Expired - Fee Related
- 2002-03-19 WO PCT/JP2002/002585 patent/WO2002074342A1/ja not_active Ceased
- 2002-03-19 BR BR0208275-6A patent/BR0208275A/pt not_active Application Discontinuation
- 2002-03-19 CN CN028095529A patent/CN1553814B/zh not_active Expired - Fee Related
- 2002-03-19 JP JP2002573049A patent/JP4499361B2/ja not_active Expired - Fee Related
- 2002-03-19 DE DE60231969T patent/DE60231969D1/de not_active Expired - Lifetime
- 2002-03-19 EP EP08021793A patent/EP2044958A3/en not_active Withdrawn
- 2002-03-19 KR KR1020037012268A patent/KR100908968B1/ko not_active Expired - Fee Related
- 2002-03-19 US US10/472,234 patent/US20040248898A1/en not_active Abandoned
- 2002-03-19 PT PT02705327T patent/PT1378246E/pt unknown
- 2002-03-19 ES ES02705327T patent/ES2324766T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60231969D1 (de) | 2009-05-28 |
| EP1378246A4 (en) | 2004-07-07 |
| WO2002074342A1 (en) | 2002-09-26 |
| JPWO2002074342A1 (ja) | 2004-07-08 |
| EP2044958A2 (en) | 2009-04-08 |
| CA2441110A1 (en) | 2002-09-26 |
| JP4499361B2 (ja) | 2010-07-07 |
| CN1553814A (zh) | 2004-12-08 |
| ATE428425T1 (de) | 2009-05-15 |
| TWI314457B (enExample) | 2009-09-11 |
| KR20030085026A (ko) | 2003-11-01 |
| CN1553814B (zh) | 2010-05-26 |
| EP1378246B1 (en) | 2009-04-15 |
| KR100908968B1 (ko) | 2009-07-22 |
| CA2441110C (en) | 2010-10-12 |
| MXPA03008440A (es) | 2004-01-29 |
| EP1378246A1 (en) | 2004-01-07 |
| US20040248898A1 (en) | 2004-12-09 |
| EP2044958A3 (en) | 2009-07-08 |
| PT1378246E (pt) | 2009-05-22 |
| ES2324766T3 (es) | 2009-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0208275A (pt) | Composições farmacêuticas para tratamento de arteriosclerose | |
| DE69724777D1 (de) | Pentafluorobenzensulfonamiden und analoge | |
| BR0113989A (pt) | Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos | |
| IS6859A (is) | Kristölluð form atorvastatíns | |
| PT989851E (pt) | Formulacao auto-emulsionante para compostos lipofilicos acidicos | |
| EE200300329A (et) | Meetod peroraalselt manustatavate epotiloonide biosaadavuse suurendamiseks ning selles kasutatav komplekt, ravimkoostis ja farmatseutiline ravimvorm | |
| BR0317715A (pt) | Composições e processos de uso de collajolie | |
| DK0639577T3 (da) | Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler | |
| BRPI0518459A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| DK1392714T3 (da) | Steroider som agonister for FXR | |
| PT911333E (pt) | Derivados de pirazolo¬4,3-d|pirimidina e composicoes farmaceuticas que os contenham | |
| NO2011026I2 (no) | Eribulin eller et farmasøytisk akseptabelt salt derav | |
| DE60131160D1 (de) | Caspase-inhibitoren und ihre verwendungen | |
| BR0307060A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
| BR0212386A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| BRPI0513672A (pt) | processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol | |
| IT1312115B1 (it) | Composti amorfi e relative composizioni farmaceutiche | |
| DE60129442D1 (de) | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten | |
| CY1106376T1 (el) | Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν | |
| CY1105939T1 (el) | Παραγωγα βενζοθειαζινης και βενζοθεαδιαζινης, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις οι οποιες τα πepιεχουν | |
| BRPI0414186A (pt) | compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto | |
| BRPI0408423A (pt) | composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação | |
| BRPI0206922B8 (pt) | composto de fragrância, composição de fragrância contendo o mesmo, e método para preparação de um composto de fragrância | |
| ATE229934T1 (de) | Sulfonamid-derivate | |
| BR9706360A (pt) | Compostos de n-benzilpiperazina novos um processo para sua preparação e para as composições farmacêuticas que os contêm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |